Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Resignation of Chief Financial Officer
On January 2, 2020, Michael MacLean, Chief Financial Officer of Akcea
Therapeutics, Inc. (the "Company") delivered to the Company a 90-day notice of
resignation from his position as Chief Financial Officer of the Company.
Mr. MacLean's resignation is effective April 1, 2020.
In accordance with the letter agreement dated October 11, 2019 (the "Letter
Agreement") entered between Mr. MacLean and the Company, Mr. MacLean will be
entitled to receive medical benefit continuation, a lump sum severance payment
equal to 12 months of his base salary, and an amount equal to his target annual
cash performance bonus for 2019.
The description of the Letter Agreement set forth above is qualified in its
entirety by reference to the full and complete terms set forth in such
agreement, which was filed as an exhibit to the Current Report on Form 8-K filed
on October 17, 2019.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses